EN
uniQure Reports Wednesday With FDA Decision Six Months Out
Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Part 2.1: Price Behavior Around Earnings
UniQure typically reports earnings before market open, meaning Day 0 represents the first trading session where investors react to results, while Day +1 captures follow-through momentum.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-07-29 | +$3.41 (+9.30%) | $4.57 (12.46%) | +$2.12 (+5.29%) | $2.64 (6.58%) |
| 2026-05-05 | +$0.48 (+2.32%) | $1.51 (7.30%) | +$1.66 (+7.84%) | $2.67 (12.62%) |
| 2026-03-02 | -$5.13 (-32.82%) | $2.13 (13.63%) | -$1.47 (-14.00%) | $0.59 (5.62%) |
| 2025-11-10 | -$1.64 (-5.90%) | $3.53 (12.70%) | +$4.69 (+17.93%) | $5.40 (20.65%) |
| 2025-07-29 | -$1.30 (-8.68%) | $2.77 (18.49%) | +$0.78 (+5.70%) | $2.02 (14.73%) |
| 2025-05-09 | +$0.54 (+4.41%) | $1.95 (15.88%) | +$0.36 (+2.81%) | $0.87 (6.82%) |
| 2025-02-27 | +$0.40 (+3.43%) | $1.08 (9.25%) | +$1.08 (+8.95%) | $1.91 (15.82%) |
| 2024-11-05 | +$0.50 (+8.99%) | $0.72 (12.95%) | +$1.10 (+18.15%) | $1.14 (18.81%) |
| Avg Abs Move | 9.48% | 12.83% | 10.09% | 12.71% |
Historical price action around earnings shows significant volatility, with an average absolute Day 0 move of 9.48% and Day +1 move of 10.09%. The most recent earnings release in July 2026 triggered a strong 9.30% gain on Day 0, followed by a 5.29% advance on Day +1, reflecting positive investor reaction despite the EPS miss. The largest single-day reaction occurred in March 2026, when the stock plunged 32.82% on Day 0 before stabilizing with a 14.00% decline on Day +1.
The data reveals substantial two-day trading ranges, averaging 12.83% on Day 0 and 12.71% on Day +1, indicating high intraday volatility as investors digest results and management commentary. Recent quarters have shown particularly dramatic swings, with November 2025 producing a 17.93% Day +1 surge despite a modest Day 0 decline. Investors should prepare for double-digit percentage moves in either direction, with the stock's reaction often extending into the second session as the market fully processes the implications of results and guidance.
Part 2.2: Options Market Expected Move
| Metric | Value |
|---|---|
| Expiration Date | 11/20/26 (DTE 17) |
| Expected Move | $4.12 (17.29%) |
| Expected Range | $19.73 to $27.97 |
| Implied Volatility | 99.99% |
The options market is pricing an expected move of 17.29% through the November 20 expiration, significantly higher than the stock's average historical Day 0 move of 9.48% and Day +1 move of 10.09%. This elevated implied volatility reflects heightened uncertainty around the upcoming release, likely driven by the recent FDA regulatory milestone and questions about the company's path to commercialization.
Part 3: What Analysts Are Saying
Analysts maintain a Strong Buy consensus on UniQure with an average price target of $58.08, implying 143% upside from the current price of $23.87. The rating breakdown shows strong bullish conviction, with 10 Strong Buy ratings, 1 Moderate Buy, and 3 Hold ratings. No analysts currently rate the stock as a sell.
However, sentiment has deteriorated over the past month. The average recommendation has declined from 4.62 to 4.50, and the number of Hold ratings increased from 2 to 3. This shift suggests some analysts are adopting a more cautious stance, likely reflecting concerns about the Advisory Committee risk and recent trial data complications.
The wide range of price targets—from a low of $25.00 to a high of $95.00—underscores the divergent views on the company's prospects. The high-end estimate reflects optimism about the Huntington's disease therapy's commercial potential, while the low-end target sits barely above current levels, indicating skepticism about near-term catalysts. Despite the recent deterioration in sentiment, the consensus still points to substantial upside if UniQure can successfully navigate the regulatory pathway and demonstrate commercial readiness.
Part 4: Technical Picture
The Barchart Technical Opinion currently shows a 40% Sell signal, unchanged from last week but representing a significant deterioration from the 24% Sell reading a month ago. This weakening technical picture reflects the stock's struggle to maintain momentum despite the recent FDA regulatory milestone.
Timeframe Analysis:
- Short-term (50% Sell): Moderate sell signal indicates near-term momentum has turned negative
- Medium-term (Hold): Neutral reading suggests the intermediate trend is in consolidation mode
- Long-term (50% Sell): Moderate sell signal reflects weakness in the longer-term trend structure
Trend Characteristics: The technical environment is characterized by a Soft signal with Weakening direction, suggesting deteriorating momentum heading into the earnings release.
The stock is trading at $23.87, positioned above its 10-day ($23.61) and 20-day ($22.88) moving averages, indicating short-term support. However, the price remains well below its 50-day ($33.57), 100-day ($38.35), and 200-day ($29.66) moving averages, confirming the longer-term downtrend. The 5-day moving average at $24.38 sits just above the current price, representing immediate resistance.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $24.38 | 50-Day MA | $33.57 |
| 10-Day MA | $23.61 | 100-Day MA | $38.35 |
| 20-Day MA | $22.88 | 200-Day MA | $29.66 |
The technical setup heading into earnings is cautionary, with the stock trapped below all major long-term moving averages and showing weakening momentum across multiple timeframes. While short-term support near the 20-day moving average at $22.88 may provide a floor, the distance from the 50-day average at $33.57 highlights the significant ground the stock needs to recover. Given the options market's expectation of a 17% move and the stock's history of volatile post-earnings reactions, traders should be prepared for a decisive break in either direction that could either challenge resistance at the 50-day average or test support at the 20-day level.